Osteoporosis across chronic liver disease

Osteoporosis International

Volumn 27, Issue 6, 2016, Pages 1967-1977

  Guarino, M ^a   Loperto, I ^a   Camera, S ^a   Cossiga, V ^a   Di Somma, C ^a   Colao, A ^a   Caporaso, N ^a   Morisco, F ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Fractures; Liver disease; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTROGEN; VITAMIN D;

ALCOHOL LIVER DISEASE; AUTOIMMUNE HEPATITIS; BONE METABOLISM; CHRONIC LIVER DISEASE; CLINICAL TRIAL (TOPIC); ESTROGEN THERAPY; HEMOCHROMATOSIS; HUMAN; INFLAMMATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TRANSPLANTATION; MINERAL SUPPLEMENTATION; NONHUMAN; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PERSONAL EXPERIENCE; PRIORITY JOURNAL; REVIEW; VIRUS HEPATITIS; VITAMIN SUPPLEMENTATION; BONE DENSITY; CHRONIC DISEASE; COMPLICATION; METABOLIC BONE DISEASE; QUALITY OF LIFE;

BONE DENSITY; BONE DISEASES, METABOLIC; CHRONIC DISEASE; HUMANS; LIVER DISEASES; OSTEOPOROSIS; QUALITY OF LIFE;

EID: 84957570028     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-016-3512-z     Document Type: Review

References (99)

1. Blachier M, Leleu H, Peck-Radosavljevic M et al (2013) The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 58(3):593–608
2. Gatta A, Verardo A, Di Pascoli M et al (2014) Hepatic osteodystrophy. Clin Cases Miner Bone Metab 11(3):185–191
3. Christodoulou S, Goula T, Ververidis A et al (2013) Vitamin D and bone disease. Biomed Res Int 2013:396–541
4. Arteh J, Narra S, Nair S (2010) Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 55(9):2624–2628
5. Hay JE (1995) Bone disease in cholestatic liver disease. Gastroenterology 108(1):276–283
6. Rouillard S, Lane NE (2001) Hepatic osteodystrophy. Hepatology 33(1):301–306
7. Krawitt EL, Grundman MJ, Mawer EB (1977) Absorption, hydroxylation, and excretion of vitamin D3 in primary biliary cirrhosis. Lancet 2(8051):1246–1249
8. WHO (2003) Prevention and management of osteoporosis. World Health Organ Tech Rep Ser 921:1–164
9. Dontas IA, Yiannakopoulos CK (2007) Risk factors and prevention of osteoporosis-related fractures. J Musculoskelet Nueronal Interact 7(3):268–272
10. Collier JD, Ninkovic M, Compston JE (2002) Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 50(Suppl 1):1–9
11. Lucaci C, Acalovschi M (2012) Hormonal and cytokine implications in the pathophysiology of osteoporosis occurring in chronic liver diseases. Maedica (Buchar) 7(4):358–363
12. Aubin JE, Triffitt JT (2002) Mesenchymal stem cells and osteoblast differentiation. Princ Bone Biol 1:59–81
13. Moschen AR, Kaser A, Stadlmann S et al (2005) The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol 43(6):973–983
14. Maheshwari A, Thuluvath P (2011) Endocrine diseases and the liver. Clin Liver Dis 15(1):55–67
15. Fede G, Spadaro L, Tomaselli T et al (2012) Adrenocortical dysfunction in liver disease: a systematic review. Hepatology 55(4):1282–1291
16. Kim CH, Takai E, Zhou H et al (2003) Trabecular bone response to mechanical and parathyroid hormone stimulation: the role of mechanical microenvironment. J Bone Miner Res 18(12):2116–2125
17. Lombardi G, Di Somma C, Rubino M et al (2011) The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics. J Endocrinol Investig 34(7 Suppl):18–22
18. Nuzzo V, Zuccoli A, De Terlizzi F et al (2013) Low 25-hydroxyvitamin d levels and low bone density assessed by quantitative ultrasonometry in a cohort of postmenopausal Italian nuns. J Clin Densitom 16(3):308–312
19. Autier P, Boniol M, Pizot C et al (2014) Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol 2(1):76–89
20. Chaney A, Heckman MG, Diehl NN et al (2015) Effectiveness and outcomes of current practice in treating vitamin D deficiency in patients listed for liver transplantation. Endocr Pract 21(7):761–769
21. Artaza JN, Norris KC (2009) Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells. J Endocrinol 200(2):207–221
22. Nobili V, Reif S (2015) Vitamin D and liver fibrosis: let’s start soon before it’s too late. Gut 64(5):698–699
23. Beilfuss A, Sowa JP, Sydor S et al (2015) Vitamin D counteracts fibrogenic TGF-beta signaling in human hepatic stellate cells both receptor-dependently and independently. Gut 64(5):791–799
24. Wang J, Zhou J, Cheng CM et al (2004) Evidence supporting dual, IGF-I-independent and IGF-I-dependent, roles for GH in promoting longitudinal bone growth. J Endocrinol 180(2):247–255
25. Weinstein RS, Jilka RL, Parfitt AM et al (1998) Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Investig 102(2):274–282
26. Mirza F, Canalis E (2015) Management of endocrine disease: secondary osteoporosis: pathophysiology and management. Eur J Endocrinol 173(3):R131–R151
27. Gupte AA, Sabek OM, Fraga D et al (2014) Osteocalcin protects against nonalcoholic steatohepatitis in a mouse model of metabolic syndrome. Endocrinology 155(12):4697–4705
28. Ducy P, Amling M, Takeda S et al (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100(2):197–207
29. Caetano-Lopes J, Canhao H, Fonseca JE (2009) Osteoimmunology—the hidden immune regulation of bone. Autoimmun Rev 8(3):250–255
30. Hackl NJ, Bersch C, Feick P et al (2010) Circulating fibronectin isoforms predict the degree of fibrosis in chronic hepatitis C. Scand J Gastroenterol 45(3):349–356
31. Wariaghli G, Mounach A, Achemlal L et al (2010) Osteoporosis in chronic liver disease: a case–control study. Rheumatol Int 30(7):893–899
32. Benetti A, Crosignani A, Varenna M et al (2008) Primary biliary cirrhosis is not an additional risk factor for bone loss in women receiving regular calcium and vitamin D supplementation: a controlled longitudinal study. J Clin Gastroenterol 42(3):306–311
33. Guanabens N, Pares A, Ros I et al (2005) Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol 42(4):573–577
34. Solaymani-Dodaran M, Card TR, Aithal GP et al (2006) Fracture risk in people with primary biliary cirrhosis: a population-based cohort study. Gastroenterology 131(6):1752–1757
35. Pares A, Guanabens N (2008) Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment. Clin Liver Dis 12(2):407–424
36. Guañabens N, Cerdá D, Monnegal A et al (2010) Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology 138(7):2348–2356
37. Mounach A, Ouzzif Z, Wariaghli G et al (2008) Primary biliary cirrhosis and osteoporosis: a case–control study. J Bone Miner Metab 26(4):379–384
38. Angulo P, Grandison GA, Fong DG et al (2011) Bone disease in patients with primary sclerosing cholangitis. Gastroenterology 140(1):180–188
39. Menon KV, Angulo P, Weston S et al (2011) Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 35(3):316–323
40. Raszeja-Wyszomirska J, Kucharski R, Zygmunt M et al (2015) The impact of fragility fractures on health-related quality of life in patients with PSC. Hepat Mon 15(4):e25539
41. 3 prevents activation of hepatic stellate cells in vitro and ameliorates inflammatory liver damage but not fibrosis in the Abcb4(−/−) model. Biochem Biophys Res Commun 459(2):227–233
42. Guggenbuhl P, Deugnier Y, Boisdet JF et al (2005) Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int 16(12):1809–1814
43. Valenti L, Varenna M, Fracanzani AL et al (2009) Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int 20(4):549–555
44. Schiefke I, Fach A, Wiedmann M (2005) Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol 11:1843–1847
45. Corey KE, Zheng H, Mendez-Navarro J et al (2012) Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis. PLoS One 7(2):e27144
46. Morisco F, Colao A, Guarino M et al (2013) Vitamin D levels and chronic hepatitis C. e-SPEN J 4(8):e169–e174
47. Fisher L, Fisher A (2007) Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol 5(4):513–520
48. Petta S, Grimaudo S, Marco VD et al (2013) Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients. J Viral Hepatol 20(7):486–493
49. Petta S, Grimaudo S, Tripodo C et al (2015) The hepatic expression of vitamin D receptor is inversely associated with the severity of liver damage in genotype 1 chronic hepatitis C patients. J Clin Endocrinol Metabol 100(1):193–200
50. Villar LM, Ronchal I, Del Campo JA (2012) Vitamin D supplementation influences sustained virological response rate in hepatitis C: a systematic review and meta-analysis. Hepatology 256(supplement 2):1024A
51. Kitson MT, Dore GJ, George J et al (2013) Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol 58(3):467–472
52. Esmat G, El Raziky M, Elsharkawy A et al (2015) Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. J Interferon Cytokine Res 35(1):49–54
53. Mandorfer M, Payer BA, Schwabl P et al (2015) Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. Liver Int 35(3):876–885
54. Di Carlo P, Siracusa L, Mazzola G et al (2015) Vitamin D and osteoporosis in HIV/HCV coinfected patients: a literature review. Int J Endocrinol 2015:969040
55. Bang CS, Shin IS, Lee SW et al (2015) Osteoporosis and bone fractures in alcoholic liver disease: a meta-analysis. World J Gastroenterol 21(13):4038–4047
56. González-Reimers E, Quintero-Platt G, Rodríguez-Rodríguez E et al (2015) Bone changes in alcoholic liver disease. World J Hepatol 7(9):1258–1264
57. González-Reimers E, García-Valdecasas-Campelo E, Santolaria-Fernández F et al (2005) Rib fractures in chronic alcoholic men: relationship with feeding habits, social problems, malnutrition, bone alterations, and liver dysfunction. Alcohol 37(2):113–117
58. Moore JB (2010) Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 69(2):211–220
59. Fabbrini E, Sullivan S, Klein S (2010) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51(2):679–689
60. Yaturu S, Humphrey S, Landry C et al (2009) Decreased bone mineral density in men with metabolic syndrome alone and with type 2 diabetes. Med Sci Monit 15(1):CR5–CR9
61. Szulc P, Varennes A, Delmas PD et al (2010) Men with metabolic syndrome have lower bone mineral density but lower fracture risk—the MINOS study. J Bone Miner Res 25(6):1446–1454
62. Jeon YK, Lee YG, Kim SS et al (2011) Association between bone mineral density and metabolic syndrome in pre and postmenopausal women. Endocr J 58(2):87–93
63. Targher G, Lonardo A, Rossini M (2015) Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link? J Endocrinol Investig 38(8):817–825
64. Li M, Xu Y, Xu M et al (2012) Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese. J Clin Endocrinol Metab 97(6):2033–2038
65. Moon SS, Lee YS, Kim SW (2012) Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women. Endocrine 42(2):423–429
66. Skoien R, Richardson MM, Jonsson JR et al (2013) Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. Liver Int 33:624–632
67. Nobili V, Giorgio V, Liccardo D et al (2014) Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease. Eur J Endocrinol 170:547–553
68. Monegal A, Navasa M, Guanabens N et al (2001) Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int 12(6):484–492
69. Hajiabbasi A, Shafaghi A, Fayazi HS et al (2015) The factors affecting bone density in cirrhosis. Hepat Mon 15(4):e26871
70. Chinnaratha MA, Chaudhary S, Doogue M et al (2015) Prevalence of hepatic osteodystrophy and vitamin D deficiency in cirrhosis. Int Med J. doi:10.1111/imj.12866
71. Trépo E, Ouziel P, Pradat P (2013) Severe vitamin D deficiency is associated with complications of portal hypertension and a worse prognosis in alcoholic cirrhosis. J Hepatol 58:S54
72. Kulak CA, Borba VZ, Kulak Júnior J et al (2014) Bone disease after transplantation: osteoporosis and fractures risk. Arq Bras Endocrinol Metab 58(5):484–492
73. Loria I, Albanese C, Giusto M et al (2010) Bone disorders in patients with chronic liver disease awaiting liver transplantation. Transplant Proc 42(4):1191–1193
74. Galtieri PA, Lattanzi B, Giusto M (2013) Bone disorders before and after liver transplantation. J Hepatol 58:S70
75. Ninkovic M, Love SA, Tom B (2001) High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int 69(6):321–326
76. Corey RL, Whitaker MD, Crowell MD et al (2014) Vitamin D deficiency, parathyroid hormone levels, and bone disease among patients with end-stage liver disease and normal serum creatinine awaiting liver transplantation. Clin Transpl 28(5):579–584
77. Guichelaar M, Malinchoc M, Sibonga J et al (2004) Immunosuppressive and postoperative effects of orthotopic liver transplantation on bone metabolism. Liver Transpl 10(5):638–647
78. Guichelaar M, Schmoll J, Malinchoc M et al (2007) Fractures and avascular necrosis before and after orthotopic liver transplantation: long-term follow-up and predictive factors. Hepatology 46(4):1198–1207
79. Guichelaar M, Kendall R, Malinchoc M et al (2006) Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl 12(9):1390–1402
80. Chaney A (2015) Primary care management of vitamin D deficiency and liver disease. J Am Assoc Nurse Pract 27(8):415–419
81. Società Italiana dell'Osteoporosi, del Metabolismo Minerale e delle Malattie dello Scheletro (2013) Guidelines for the diagnosis, prevention and treatment of osteoporosis. Minerva Endocrinol 38:1–30
82. Maimoun L, Sultan C (2011) Effects of physical activity on bone remodeling. Metabolism 60(3):373–388
83. Zelber-Sagi S, Ratziu V, Oren R (2011) Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol 17(29):377–389
84. Peng L, Wang J, Li F (2011) Weight reduction for non-alcoholic fatty liver disease. Cochrane Database Syst Rev 15(6):CD003619
85. Brandi ML (2012) Evaluation of fracture risk and fracture prevention: an Italian picture. Clin Cases Miner Bone Metab 9(2):73–75
86. Otaka Y (2013) Fall risk and fracture. Secondary prevention of falls after sustaining a fall-related fracture. Clin Calcium 23(5):739–744
87. Asano S, Suzuki A (2013) Assessment of the treatment of glucocorticoid-induced osteoporosis. Clin Calcium 23(3):401–408
88. Pereira RM, Carvalho JF, Paula AP et al (2012) Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Reumatol 52(4):580–593
89. Hagino H (2015) Vitamin D3 analogs for the treatment of osteoporosis. Can J Physiol Pharmacol 93(5):327–332
90. Institute of Medicine of the National Academies. DRIs for calcium and Vitamin D. Washington (DC): National Academy of Sciences; 2010. http://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/DRI-Values.aspx. Accessed Jan 1
91. Guanabens N, Pares A, Ros I et al (2003) Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 98(10):2268–2274
92. Zein CO, Jorgensen RA, Clarke B et al (2005) Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 42(4):762–771
93. Monegal A, Guanabens N, Suarez MJ et al (2009) Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial. Transpl Int 22(2):198–206
94. Atamaz F, Hepguler S, Karasu Z et al (2006) The prevention of bone fractures after liver transplantation: experience with alendronate treatment. Transplant Proc 38(5):1448–1452
95. Shane E, Cohen A, Stein EM (2012) Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation. J Clin Endocrinol Metab 97:4481–4490
96. Weitzmann MN, Pacifici R (2006) Estrogen deficiency and bone loss: an inflammatory tale. J Clin Investig 116(5):1186–1194
97. O'Donohue J, Williams J (1997) Hormone replacement therapy in women with liver disease. B J Obstet Gynaecol 104(1):1–3
98. Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C (2011) Hormone replacement for osteoporosis in women with primary biliary cirrhosis. Cochrane Database Syst Rev 7(12):CD009146
99. Ormarsdottir S, Mallmin H, Naessen T et al (2004) An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. J Intern Med 256(1):63–69